CorMedix Inc. Stock price

Equities

CRMD

US21900C3088

Pharmaceuticals

Market Closed - Nasdaq 04:30:00 2024-03-28 pm EDT 5-day change 1st Jan Change
4.24 USD +1.92% Intraday chart for CorMedix Inc. +8.72% +12.77%
Sales 2024 * 25.16M Sales 2025 * 81.93M Capitalization 233M
Net income 2024 * -45M Net income 2025 * 6M EV / Sales 2024 * 11.9 x
Net Debt 2024 * 67.4M Net Debt 2025 * 48.88M EV / Sales 2025 * 3.44 x
P/E ratio 2024 *
-5.73 x
P/E ratio 2025 *
-44.6 x
Employees 83
Yield 2024 *
-
Yield 2025 *
-
Free-Float 98.97%
More Fundamentals * Assessed data
Dynamic Chart
1 day+1.92%
1 week+8.72%
Current month+19.77%
1 month+19.77%
3 months+9.56%
6 months+14.91%
Current year+12.77%
More quotes
1 week
3.92
Extreme 3.92
4.26
1 month
3.03
Extreme 3.03
4.40
Current year
2.89
Extreme 2.89
4.40
1 year
2.57
Extreme 2.57
6.09
3 years
2.57
Extreme 2.57
10.40
5 years
2.16
Extreme 2.16
18.80
10 years
0.86
Extreme 0.8605
52.00
More quotes
Managers TitleAgeSince
Chief Executive Officer 48 22-03-17
Director of Finance/CFO 47 20-05-10
Chief Tech/Sci/R&D Officer - 21-12-31
Members of the board TitleAgeSince
Chairman 79 16-04-26
Director of Finance/CFO 68 11-08-14
Director/Board Member 70 19-02-28
More insiders
Date Price Change Volume
24-03-28 4.24 +1.92% 339,828
24-03-27 4.16 +1.22% 379,826
24-03-26 4.11 +0.74% 486,857
24-03-25 4.08 +4.08% 489,686
24-03-22 3.92 +0.51% 381,421

Delayed Quote Nasdaq, March 28, 2024 at 04:30 pm EDT

More quotes
CorMedix Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases. The Company is focused on commercializing its lead product DefenCath, which is an antimicrobial catheter lock solution approved to reduce the incidence of catheter-related bloodstream infections in adult patients with kidney failure receiving chronic hemodialysis through a central venous catheter. DefenCath is a formulation of taurolidine 13.5 mg/mL, and heparin 1000 USP Units/mL indicated to reduce the incidence of catheter-related bloodstream infections (CRBSI) in adult patients with kidney failure receiving chronic hemodialysis through a central venous catheter (CVC). In addition to DefenCath, the Company has sponsored a pre-clinical research collaboration for the use of taurolidine as a possible treatment for rare pediatric tumors.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
D
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
4.24 USD
Average target price
13 USD
Spread / Average Target
+206.60%
Consensus
  1. Stock
  2. Equities
  3. Stock CorMedix Inc. - Nasdaq